Latest Security News

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.

Change Financial Limited reported a record Q4 FY25 revenue of US$4.0 million, marking a 26% year-on-year increase, alongside positive underlying EBITDA and a strong outlook for FY26.

Aroa Biosurgery has reported its third consecutive quarter of positive net cash flow, maintaining a strong cash position and reaffirming its FY26 revenue and EBITDA guidance. The company’s Myriad product sales continue to grow, supported by new clinical evidence.

Osmond Resources has confirmed the award of the Orión Investigation Permit in Spain and is set to begin an initial drilling program this quarter, advancing its EU Critical Minerals Project amid strong regulatory support.

Greatland Resources has completed a landmark FY25, integrating Telfer and Havieron operations, producing nearly 200,000 ounces of gold, and raising $490 million in a successful ASX IPO. The company sets ambitious FY26 targets focused on extending Telfer’s mine life through its largest drilling program ever.

Spacetalk Ltd reports robust growth in paid mobile subscribers and recurring revenue for Q4 FY25, supported by strategic capital raises and international expansion.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

Terramin Australia reports steady progress across multiple projects including key drilling at Tala Hamza and regulatory approvals at Kapunda, while navigating legal challenges at Bird in Hand. Algeria’s recent mining reforms offer a promising backdrop for the company’s expansion plans.

New World Resources has upgraded its Antler Copper Deposit resource to 14.2 million tonnes at 3.8% copper equivalent, secured key permitting milestones, and recommended shareholders accept a $0.067 per share takeover offer from Kinterra Capital.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.